Praxis Precision Medicines I (PRAX) Institutional Investor Snapshot (317 Funds, Q2 2026)

PRAX ranks #1999 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

PRAX is a top-conviction position for Cormorant Asset Management, LP — at 11.0% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in PRAX belongs to Jupiter Topco LLC, but the position matters far more to Cormorant Asset Management, LP, who has 11.0% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Fidelity has added to its PRAX position for two straight quarters, increasing it by $375.2M to reach $775.7M today.

Barclays PLC has trimmed its PRAX position for two straight quarters, cutting it by $154.4M while still holding $2.0M.

PRAX is up 1.1% today, and institutions have been net buyers of $3.2B this quarter — today's price move and the underlying institutional flow are pointing the same direction.

PRAX reported a net loss of $339.1M over the trailing twelve months.

• Not yet profitable — net loss of $339.1M over the trailing twelve months
• Revenue declined 100.0% year over year
• Net income declined year over year, from -$251.0M to -$339.1M
• Operating cash flow was negative, using $249.1M in cash
• Current ratio of 10.22x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.07x equity — within a conventional range